You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 4, 2025

CLINICAL TRIALS PROFILE FOR HYDROXOCOBALAMIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for hydroxocobalamin

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT03446599 ↗ Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery Withdrawn Dartmouth-Hitchcock Medical Center Phase 2 2019-11-01 This is a pilot study to determine the hemodynamic effects when hydroxocobalamin vs methylene blue is administered during cardiopulmonary bypass in patients at risk of vasoplegia by measuring mean arterial pressure (MAP), systemic vascular resistance (SVR) and vasopressor requirement.
NCT03735316 ↗ Vitamin B12a Vasoplegic Syndrome Recruiting Mayo Clinic Phase 2 2019-04-25 The study team will evaluate the medication Hydroxocobalamin (B12a) for treatment of low blood pressure after cardiac surgery.
NCT03372447 ↗ Megadose of Hydroxocobalamin for the Treatment of Pernicious Anemia Completed Hospital Universitario Dr. Jose E. Gonzalez Phase 4 2017-12-27 Demonstrate the effectiveness of a single dose of a multivitamin complex for the treatment of megaloblastic anemia
NCT02270749 ↗ Vitamin Deficiencies and Suppletion in Morbid Obesity Completed Rijnstate Hospital Phase 4 2014-10-01 The purpose of this study is to evaluate the most effective treatment for patients who underwent a Roux-en-Y gastric bypass and developed postoperatively a vitamin B12 deficiency.
NCT01656616 ↗ Hydroxycobalamin and Rural Emergency Medical Services Cyanide Exposure Patients: A Cost Analysis Withdrawn Maine Medical Center 2012-08-01 The costs to a rural emergency medical services (EMS) system of a change from a traditional cyanide antidote kit to a kit containing hydroxocobalamin alone are currently unknown. The purpose of this study is to use current EMS data to calculate the costs to a rural EMS system associated with the adoption of a hydroxocobalamin protocol for the treatment of suspected cyanide exposure.
NCT01656616 ↗ Hydroxycobalamin and Rural Emergency Medical Services Cyanide Exposure Patients: A Cost Analysis Withdrawn MaineHealth 2012-08-01 The costs to a rural emergency medical services (EMS) system of a change from a traditional cyanide antidote kit to a kit containing hydroxocobalamin alone are currently unknown. The purpose of this study is to use current EMS data to calculate the costs to a rural EMS system associated with the adoption of a hydroxocobalamin protocol for the treatment of suspected cyanide exposure.
NCT01147289 ↗ Efficacy and Safety of Injectable Association of Dexamethasone, Dipyrone and Hydrocobalamin in Lumbar Sciatic Pain Completed Eurofarma Laboratorios S.A. Phase 3 2011-02-01 A phase III, randomized, multicenter, open label clinical trial to evaluate efficacy and safety of the injectable association of dexamethasone, dipyrone, and hydroxocobalamin in lumbar sciatic pain. The study will enroll 140 patients in each arm (280 total).
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 7 of 7 entries

Clinical Trial Conditions for hydroxocobalamin

Condition Name

21110-0.200.20.40.60.811.21.41.61.822.2Vasoplegic SyndromeCyanide PoisoningVitamin B12 DeficiencyHypotension[disabled in preview]
Condition Name for hydroxocobalamin
Intervention Trials
Vasoplegic Syndrome 2
Cyanide Poisoning 1
Vitamin B12 Deficiency 1
Hypotension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

3211000.511.522.53VasoplegiaSyndromePoisoningColitis, Ulcerative[disabled in preview]
Condition MeSH for hydroxocobalamin
Intervention Trials
Vasoplegia 3
Syndrome 2
Poisoning 1
Colitis, Ulcerative 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for hydroxocobalamin

Trials by Country

+
Trials by Country for hydroxocobalamin
Location Trials
United States 8
Brazil 3
Saudi Arabia 2
Mexico 1
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for hydroxocobalamin
Location Trials
Massachusetts 2
New York 1
Florida 1
Wisconsin 1
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for hydroxocobalamin

Clinical Trial Phase

30.0%10.0%40.0%20.0%011.522.533.54Phase 4Phase 3Phase 2[disabled in preview]
Clinical Trial Phase for hydroxocobalamin
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 2 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

45.5%27.3%18.2%9.1%011.522.533.544.55RecruitingCompletedWithdrawn[disabled in preview]
Clinical Trial Status for hydroxocobalamin
Clinical Trial Phase Trials
Recruiting 5
Completed 3
Withdrawn 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for hydroxocobalamin

Sponsor Name

trials011223344Mayo ClinicJoshua KorzenikDammam University[disabled in preview]
Sponsor Name for hydroxocobalamin
Sponsor Trials
Mayo Clinic 2
Joshua Korzenik 1
Dammam University 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

83.3%16.7%0-101234567891011OtherIndustry[disabled in preview]
Sponsor Type for hydroxocobalamin
Sponsor Trials
Other 10
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Hydroxocobalamin Market Analysis and Financial Projection

Hydroxocobalamin: Clinical Trials, Market Analysis, and Projections

Introduction to Hydroxocobalamin

Hydroxocobalamin, a form of vitamin B12, is a crucial medication used in various therapeutic areas, including the treatment of cyanide poisoning, megaloblastic anemia, and vitamin B12 deficiency. Here, we will delve into the current state of clinical trials, market analysis, and future projections for hydroxocobalamin.

Clinical Trials Update

Ongoing and Completed Trials

Hydroxocobalamin is involved in several clinical trials across different phases and indications. Here are some key updates:

  • Cyanide Poisoning: Hydroxocobalamin has been approved and is widely used for treating cyanide poisoning. Clinical trials continue to evaluate its efficacy and safety in this context. For example, a Phase 4 trial (NCT04259060) has been conducted to compare hydroxocobalamin with methylene blue in treating cyanide poisoning[1].

  • Cardiopulmonary Bypass: A Phase 2 trial investigated the use of hydroxocobalamin in patients undergoing cardiopulmonary bypass surgery. The trial aimed to assess the drug's impact on reducing homocysteine levels and improving patient outcomes[1].

  • Vitamin B12 Deficiency: Numerous trials are focused on treating vitamin B12 deficiency, particularly in regions with high prevalence rates. For instance, India has a significant number of clinical trials addressing hypocobalaminemia (vitamin B12 deficiency), with hydroxocobalamin being one of the prominent treatments[3].

Regional Distribution of Trials

Clinical trials for hydroxocobalamin are conducted globally, but some regions are more active than others:

  • Asia-Pacific: This region, particularly India, has the highest number of clinical trials for hypocobalaminemia, indicating a strong focus on addressing vitamin B12 deficiency in this area[3].

  • North America and Europe: These regions also host a significant number of trials, with the US and Germany being among the top countries for conducting clinical trials related to hydroxocobalamin[3].

Sponsor and Phase Distribution

The clinical trials are sponsored by various institutions and companies, including pharmaceutical companies and research centers. The distribution by phase includes:

  • Phase 2 and Phase 4 Trials: These phases are more common for hydroxocobalamin, with trials focusing on its efficacy in different clinical settings[1][3].

Market Analysis

Global Vitamin B12 Market

The global vitamin B12 market, which includes hydroxocobalamin, is projected to grow significantly over the next few years.

  • Market Size and Growth: The global vitamin B12 market is valued at around USD 288 million in 2024 and is expected to grow at a compound annual growth rate (CAGR) of approximately 9.19% from 2024 to 2030[5].

  • Segmentation by Product: Hydroxocobalamin is one of the key forms of vitamin B12, alongside cyanocobalamin, methylcobalamin, and adenosylcobalamin. While cyanocobalamin is the most commonly used form due to its stability and cost-effectiveness, hydroxocobalamin is gaining traction due to its superior bioavailability[2].

  • Segmentation by Vertical: The market is segmented into food and beverages, pharmaceuticals, animal feed, dietary supplements, and others. Hydroxocobalamin is primarily used in the pharmaceutical and dietary supplement sectors[2].

Regional Market Outlook

  • Asia-Pacific: This region is expected to dominate the market due to the growing cases of malnutrition and vitamin deficiencies, especially among the younger population and those following plant-based diets[5].

  • North America and Europe: These regions also show significant growth, driven by increasing awareness of the health benefits of vitamin B12 supplements[5].

Projections and Future Outlook

Growing Demand

The demand for hydroxocobalamin is expected to increase due to several factors:

  • Increasing Prevalence of Deficiency: The rising prevalence of vitamin B12 deficiency, particularly in regions with limited access to balanced diets, will drive the demand for hydroxocobalamin[5].

  • Awareness and Health Trends: Growing awareness about the health benefits of vitamin B12, including its role in maintaining healthy blood and nerve cells, will continue to boost the market[5].

Technological and Formulation Advancements

  • Route of Administration: The market is seeing advancements in the route of administration, with intramuscular injections being the most common but oral, subcutaneous, and nasal forms also gaining popularity[2].

  • Formulations: New formulations such as nasal gels and sprays are being developed to improve patient compliance and bioavailability[2].

Key Applications and Indications

Therapeutic Areas

Hydroxocobalamin is used in several therapeutic areas:

  • Cyanide Poisoning: It is the primary treatment for cyanide poisoning due to its ability to bind with cyanide ions and form a less toxic compound[1].

  • Megaloblastic Anemia: Hydroxocobalamin is used to treat megaloblastic anemia caused by vitamin B12 deficiency[1].

  • Neuralgia and Nerve Damage: It is also used to treat neuralgia and nerve damage, including conditions like diabetic nerve damage and shingles-related nerve pain[1].

Preventive Use

  • Prevention of Deficiency: Hydroxocobalamin is prescribed to prevent vitamin B12 deficiency in individuals at risk, such as those with pernicious anemia or following a vegan diet[1].

Conclusion

Hydroxocobalamin is a vital medication with a strong presence in clinical trials and a growing market. As awareness about vitamin B12 deficiency increases and the global population becomes more health-conscious, the demand for hydroxocobalamin is expected to rise significantly.

Key Takeaways

  • Clinical Trials: Hydroxocobalamin is involved in various clinical trials, particularly in Asia-Pacific and North America, addressing indications like cyanide poisoning and vitamin B12 deficiency.
  • Market Growth: The global vitamin B12 market, including hydroxocobalamin, is projected to grow at a CAGR of 9.19% from 2024 to 2030.
  • Regional Dominance: Asia-Pacific is expected to dominate the market due to high prevalence rates of malnutrition and vitamin deficiencies.
  • Therapeutic Applications: Hydroxocobalamin is used in treating cyanide poisoning, megaloblastic anemia, and neuralgia, among other conditions.

FAQs

What is the primary use of hydroxocobalamin?

Hydroxocobalamin is primarily used to treat cyanide poisoning and vitamin B12 deficiency, including conditions like megaloblastic anemia and neuralgia.

Which region is expected to dominate the vitamin B12 market?

Asia-Pacific is expected to dominate the vitamin B12 market, driven by the growing cases of malnutrition and vitamin deficiencies in this region.

What is the projected CAGR for the global vitamin B12 market?

The global vitamin B12 market is projected to grow at a CAGR of approximately 9.19% from 2024 to 2030.

What are the different forms of vitamin B12 available in the market?

The different forms include cyanocobalamin, hydroxocobalamin, methylcobalamin, adenosylcobalamin, and others.

How is hydroxocobalamin administered?

Hydroxocobalamin can be administered via intramuscular injection, subcutaneous injection, orally, or through nasal forms.

Sources

  1. Synapse: Hydroxocobalamin - Drug Targets, Indications, Patents[1].
  2. MarketsandMarkets: Vitamin B12 Market Trends, Drivers & Opportunities[2].
  3. GlobalData: Hypocobalaminemia (Vitamin B12) Deficiency Clinical Trial Analysis[3].
  4. Aetna: Vitamin B-12 Therapy - Medical Clinical Policy Bulletins[4].
  5. MarkNtel Advisors: Global Vitamin B12 Market Share, Industry Size, Forecast 2030[5].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.